Luc Debruyne

GSK Vaccines

As President of GSK’s global vaccines business, Luc Debruyne oversees a world-leading enterprise delivering vaccine to 90% of the world’s countries and more than £3 billion in annual revenue to GSK.
Appointed to the role as President in 2013, Luc’s ambition for the business is to lead the industry in improving health globally, continuously delivering better vaccines and protecting more people while running our business sustainably.

Following GSK’s acquisition of Novartis Vaccines in early 2015, Luc has presided over the integration of two great global organisations and has further reinforced GSK’s position as the leader in the field of vaccines.

Luc is passionate about the role GSK plays in improving health globally, protecting people around the world against life threatening diseases. Together with a team of more than 16,000 talented individuals, Luc is focussed on ensuring the reliable supply of high quality vaccines around the world, boosting innovation and on building a values-based high performance culture.
Luc joined GSK in 1991 and has held a variety of roles with increasing responsibility since then, most recently as Senior Vice President for Europe.

None yet.